Citations 1
First-in-Human Clinical Experience With Focal Pulsed Field and Radiofrequency Dual-Modality Ablation for Treatment Refractory Left Ventricular Summit PVCs
Patil, Shivaraj, Liu, Xiaoke Ken, Siontis, Konstantinos C. , Prasitlumkum, Narut , Asirvatham, S, Cha, Yong‐Mei , Munoz, Freddy Del‐Carpio , Deshmukh, Abhishek , DeSimone, Christopher V. , Friedman, Paul A. , Madhavan, Malini , Mulpuru, S K, Munger, Thomas, Nguyen, Duy T. , Tan, N, Sugrue, Alan , Killu, Ammar M. , Asirvatham, Samuel J. , Liu, Xiaoke , Asirvatham, Samuel J , Del-Carpio Munoz, Freddy , Deshmukh, Abhishek J , Ezzeddine, Fatima , Friedman, Paul A , Kowlgi, Narayan G , Madhavan, Malini , Mulpuru, Siva K , Nguyen, Duy, Noseworthy, Peter A , Tan, Nicholas , Sugrue, Alan , Kapa, Suraj , Killu, Ammar M , DeSimone, Christopher V , Prasitlumkum, Narut , Ezzeddine, Fatima M. , Kowlgi, Gurukripa N. , Mulpuru, Siva K. , Munger, Thomas M., Noseworthy, Peter A. , Kapa, Suraj
Circulation: Arrhythmia and Electrophysiology | April 24, 2026 | Volume: 19 | Issue: 6 | Pages: No page available
BACKGROUND: Radiofrequency (RF) ablation of premature ventricular complexes (PVCs) originating from the left ventricular summit may be unsuccessful, highlighting the need for alternative approaches. We aimed to assess the efficacy and safety of a novel dual-modality focal catheter in treating left ventricular summit PVCs in patients who had failed previous RF ablation. METHODS: Patients were prospectively enrolled and underwent a redo ablation procedure using an irrigated, contact-force sensing, dual-modality focal catheter (TactiFlex Duo, Abbott) under compassionate use indication. The ablation strategy, including the choice of energy modality (monopolar pulsed field [PF], RF, or both), was left to the operator’s discretion. Safety assessments included serial biomarkers, renal function, and CMR within 36 hours. Efficacy was defined as ≥80% reduction in PVC burden with symptom resolution at 3-month follow-up. RESULTS: Six consecutive patients (4 men; mean age, 53.8±15 years) with symptomatic left ventricular summit PVCs and a prior failed RF ablation (range, 1–2) were prospectively enrolled. All PVCs had an inferior axis, with a left bundle V1 morphology observed in 4 of 6 cases (mean burden, 30.1±5.3%). Acute suppression of PVCs was achieved in all cases. Acute suppression with a single PF application in the great cardiac vein-anterior interventricular vein occurred in 2 patients, while 3 patients required additional RF, PF, or combined RF+PF applications at adjacent sites. One patient with an inaccessible great cardiac vein-anterior interventricular vein was successfully treated in the left ventricular outflow tract with RF+PF application. Transient, reversible left anterior descending vasospasm was observed during PF delivery in 2 of 5 cases that underwent PF application adjacent to a coronary artery, despite pretreatment with intracoronary nitroglycerin without ECG or hemodynamic sequelae. All patients had durable suppression of PVCs at follow-up. CONCLUSIONS: In its first human application, dual-modality ablation was feasible and effective for refractory left ventricular summit PVCs. Transient coronary vasospasm occurred, though it was reversible and without acute clinical consequences.